Transcept Pharmaceuticals to Report First Quarter 2012 Financial Results and Host Conference Call on May 14, 2012
Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, today announced that the company will host a conference call on Monday, May 14, 2012, at 4:30 p.m. Eastern Time to discuss its first quarter 2012 financial results. The conference call will follow the release of the Transcept first quarter 2012 financial results after the close of market that day.
Conference Call Information Date: Monday, May 14, 2012 Time: 4:30 p.m. ET Dial-in (U.S.): 877-638-4558 Dial-in (International): 914-495-8537
A simultaneous webcast of the conference call will be available on the Investors section of the Transcept website at www.transcept.com. A replay of this webcast will be available on the website shortly after the conclusion of the call through July 31, 2012.
A telephone replay of the conference call will be available shortly after the conclusion of the call through May 19, 2012. The replay telephone number is 855-859-2056 (U.S.) or 404-537-3406 (International), replay passcode: 77576088.
About TransceptTranscept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience. Intermezzo® (zolpidem tartrate) sublingual tablet C-IV is the first FDA approved Transcept product. Purdue Pharma holds commercialization and development rights for Intermezzo in the United States. Transcept is currently conducting a Phase 2 study of an investigational product, TO-2061, in patients with obsessive-compulsive disorder. For further information about Transcept, please visit www.transcept.com. For information about Intermezzo, please visit www.IntermezzoRx.com.
Contact:Transcept Pharmaceuticals, Inc.Greg MannSr. Director, Corporate Communications(510) 215-3567gmann@transcept.com
SOURCE Transcept Pharmaceuticals, Inc.
